Navigation Links
Quest Diagnostics Announces Completion of Final Extension of the Subsequent Offering Period and Intent to Exercise Top-Up Option and Complete Merger
Date:5/11/2011

MADISON, N.J., May 11, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, and Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), announced today the completion of the final extension of the subsequent offering period with respect to Spark's cash tender offer for all outstanding shares of common stock of Celera Corporation (NASDAQ: CRA).  The final extension of the subsequent offering period for the tender offer expired at 5:00 p.m., New York City time, on Tuesday, May 10, 2011.  Computershare Trust Company, N.A., the depositary for the tender offer, has indicated that 1,492,309 shares of common stock of Celera had been tendered during the final extension of the subsequent offering period and Spark has accepted for payment all tendered shares.  Spark now owns approximately 53,215,043 shares of common stock of Celera, representing approximately 64.02% of Celera's outstanding shares of common stock and 61.01% of Celera's outstanding shares of common stock on a fully diluted basis (as determined pursuant to the merger agreement).

Quest Diagnostics also announced that, following receipt by the depositary for the tender offer of the requisite documents in respect of the Celera shares of common stock that were tendered in accordance with the guaranteed delivery procedures, Spark intends to exercise its option under the merger agreement (the "top-up option") to purchase directly from Celera an additional number of shares sufficient to give it ownership of one share more than 90% of Celera's outstanding shares when combined with the shares it purchased in the tender offer, and purchase additional shares from Celera at a purchase price of $8.00 per share (payable in a combination of cash and a promissory note), which together with the shares purchased in the tender offer, will represent at least 90% of the outstanding shares of Celera.  Quest Diagnostics then intends to effect a "short-form" merger under Delaware law as promptly as practicable following the exercise of the top-up option, without the need for a meeting of Celera stockholders.

As a result of the merger, the remaining Celera stockholders (other than Celera, Quest Diagnostics, Spark and any of their respective direct or indirect wholly owned subsidiaries, or those stockholders who properly exercise appraisal rights under Delaware law) will receive the same $8.00 per share price, in cash, without interest and subject to any required withholding of taxes, that was paid in the tender offer.  After the merger, Celera will be a wholly owned subsidiary of Quest Diagnostics, Celera shares will cease to be traded on the NASDAQ Global Select Market and Celera will no longer have reporting obligations under the Securities Exchange Act of 1934, as amended.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions.  The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff.  Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.  Additional company information is available at: www.questdiagnostics.com.

Forward Looking Statements

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Quantitative and Qualitative Disclosures About Market Risk" in the company's 2010 Annual Report on Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Quantitative and Qualitative Disclosures About Market Risk" and "Risk Factors" in the company's 2011 Quarterly Reports on Form 10-Q and other items throughout the Form 10-K and the company's 2011 Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Contacts:
For Quest Diagnostics: Kathleen Valentine (Investors), +1-973-520-2900,
or Gary Samuels (Media), +1-973-520-2800


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Sponsors American Cancer Societys Choose You® Movement
2. Quest Diagnostics Announces Final Extension of Subsequent Offering Period for Shares of Celera
3. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
4. Quest Diagnostics Launches Simplexa™ C. Difficile Universal Direct Test in Europe
5. Quest Diagnostics Announces One Day Extension of Offer to Acquire Celera to 5pm Today
6. Patient Advocates File FOIA Request to FDA on Avastin
7. Shareholders to Challenge Johnson & Johnsons Support for Left-Wing Policy Agenda: CEO William C. Weldon to Be Questioned on Firms Failure to Disclose Financial Information on Firms ObamaCare Lobbying It Pledged to Release Last Year
8. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
9. PLC Systems Chief Financial Officer to Leave Company to Become CEO of Clinquest
10. Quest Diagnostics Launches Hepatitis C Virus Therapy Test Based on IL28B Gene Variants
11. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)...  Venice,s newest laser clinic, Physicians Advanced ... kind in the area and specializes in the ... The physician-owned and operated laser clinic is taking ... with its revitalizing skin care approach, unprecedented eVisit ... technology. http://photos.prnewswire.com/prnh/20160204/329957 --> ...
(Date:2/5/2016)... , Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: ... care products and services to office-based dental, animal health ... into an agreement to acquire a majority ownership interest ... and equipment in Brazil . ... in Blumenau, Brazil, Dental Cremer is the dental distribution business ...
(Date:2/4/2016)... Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, announced today ... (ASR) agreement with Morgan Stanley & Co. LLC to ... is part of the Company,s previously authorized program to ... stock.  --> --> ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... search for and donate to Give To Cure’s campaign that is crowdfunding clinical trials ... users make and share payments through a smart device. In 2015 alone, Venmo processed ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point ... Best in KLAS: Software & Services for HIT Implementation Support & Staffing report ... independently ranks vendor performance by healthcare executives, managers and clinicians representing over 4,500 ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Ben Amini, a ... is now welcoming orthodontist, Dr. Amanda Cheng, to the practice. With the addition ... health care, including general dentistry, cosmetic treatments, periodontics, implant dentistry , endodontics, ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the ... a dream. A hallmark feature of patients with eating disorders is significant self-criticism, and ... disorder behaviors and obsessions are regarded as maladaptive means for coping with this unease, ...
Breaking Medicine News(10 mins):